Pancreatic Adeno-MiNEN, a Rare Newly Defined Entity with Challenging Diagnosis and Treatment: A Case Report with Systematic Literature Review and Pooled Analysis.

MiNEN mixed neuroendocrine-non neuroendocrine neoplasm pancreatic tumour

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
26 Aug 2022
Historique:
received: 25 07 2022
revised: 20 08 2022
accepted: 22 08 2022
entrez: 9 9 2022
pubmed: 10 9 2022
medline: 10 9 2022
Statut: epublish

Résumé

Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) are a peculiar entity that can occur throughout the whole gastrointestinal trait, and pancreatic localization is rare. Their main characteristic is the presence of at least a neuroendocrine and an epithelial component, each accounting for at least 30% of the tumour mass. The presence of epithelial ductal component defines adeno-MiNEN. We report a case of a 59-year-old woman affected by pancreatic adeno-MiNEN with challenging diagnosis and successfully treated. A systematic literature review and pooled analysis was also performed, aiming to define the management and outcomes of pancreatic adeno-MiNEN. Out of 190 identified records, 15 studies including 28 patients affected by pancreatic-adeno-MiNEN were included in the analysis. Pancreatic adeno-MiNEN occurred mainly in males (82.8%) and at a mean age of 61.7 (range: 24-82) years. Pre-operative diagnosis was possible only in 14.2% of cases. At presentation, the majority had already advanced disease (TNM stage III (53.8%) and stage IV 19.3%). Adjuvant therapy was performed in 55% of patients, and the tumour recurrence rate was in 30% of cases. Median disease-free survival (DFS) was 12 months (range: 0-216 months) with a 5-year DFS of 16.6%, while the median overall survival (OS) was 12 months (range: 0-288 months) with a 5-year OS of 23.5%. Pancreatic adeno-MiNENs are rare; as they have very heterogenous behaviour, they are rarely diagnosed preoperatively and have poor prognosis. Treatment of localised MiNEN still relies on radical surgical resection, which seems essential to achieve a good oncological prognosis. International registry on MiNEN is necessary to improve the knowledge on this rare tumour and to improve its outcomes.

Identifiants

pubmed: 36078951
pii: jcm11175021
doi: 10.3390/jcm11175021
pmc: PMC9457227
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Balkan Med J. 2018 Mar 19;35(3):263-267
pubmed: 29551754
Neuroendocrinology. 2017 Feb 11;105(3):196-200
pubmed: 28190015
Medicine (Baltimore). 2015 Dec;94(48):e2156
pubmed: 26632896
Virchows Arch. 1999 Dec;435(6):606-11
pubmed: 10628803
Cancers (Basel). 2012 Jan 16;4(1):11-30
pubmed: 24213223
Neuroendocrinology. 2017 Feb 25;105(3):255-265
pubmed: 28237989
Pathol Int. 2002 Nov;52(11):740-6
pubmed: 12685552
Neuroendocrinology. 2017;105(4):412-425
pubmed: 28803232
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861
pubmed: 30487695
Cancer. 2014 Sep 15;120(18):2814-23
pubmed: 24771552
J Surg Oncol. 2008 Apr 1;97(5):469-75
pubmed: 18161862
BMJ Case Rep. 2011 Apr 19;2011:
pubmed: 22696627
Histopathology. 2002 Aug;41(2):122-6
pubmed: 12147089
JOP. 2005 Sep 10;6(5):449-54
pubmed: 16186667
Pancreas. 2013 Apr;42(3):429-35
pubmed: 23462323
Virchows Arch. 2021 Jun;478(6):1215-1219
pubmed: 33005981
BMJ Case Rep. 2020 Apr 27;13(4):
pubmed: 32345587
Surg Case Rep. 2016 Dec;2(1):133
pubmed: 27848241
Medicine (Baltimore). 2017 Mar;96(9):e6225
pubmed: 28248881
Expert Rev Anticancer Ther. 2019 Dec;19(12):1029-1050
pubmed: 31738624
Int Surg. 2011 Apr-Jun;96(2):153-8
pubmed: 22026308
Ann Endocrinol (Paris). 2019 Jun;80(3):172-173
pubmed: 31064662
Endocr Pathol. 2016 Dec;27(4):284-311
pubmed: 27169712
Pancreatology. 2021 Jan;21(1):224-235
pubmed: 33309225
Med Mol Morphol. 2011 Mar;44(1):58-62
pubmed: 21424939

Auteurs

Roberta Angelico (R)

HPB and Transplant Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.

Leandro Siragusa (L)

HPB and Transplant Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.

Cristine Brooke Pathirannehalage Don (CB)

HPB and Transplant Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.

Bruno Sensi (B)

HPB and Transplant Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.

Federica Billeci (F)

HPB and Transplant Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.

Leonardo Vattermoli (L)

Department of Diagnostic Imaging and Interventional Radiology, Tor Vergata University of Rome, 00133 Rome, Italy.

Belen Padial (B)

Histopathologic Unit, Tor Vergata University of Rome, 00133 Rome, Italy.

Giampiero Palmieri (G)

Histopathologic Unit, Tor Vergata University of Rome, 00133 Rome, Italy.

Alessandro Anselmo (A)

HPB and Transplant Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.

Alessandro Coppola (A)

Department of Surgery, University Campus Bio-Medico of Rome, 00128 Rome, Italy.

Giuseppe Tisone (G)

HPB and Transplant Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.

Tommaso Maria Manzia (TM)

HPB and Transplant Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00133 Rome, Italy.

Classifications MeSH